People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharmaceuticals, Biotechnology, Manufacturing, Mining & Resources
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. | — | Pharmaceuticals | Growth/Late | $493.0M | $17.9B | 2020 |
| Beam Therapeutics Inc. | — | Pharmaceuticals | Series D+ | $218.6M | $4.8B | 2018 |
| Sienna Biopharmaceuticals, Inc. | — | Biotechnology | Series C | $58.9M | $1.7B | 2015 |
| Axion Power International, Inc. | — | Manufacturing | Series B | $44.4M | $102.7M | 2009 |
| Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) | — | Pharmaceuticals | Series A | $30.5M | $334.7M | 2009 |
| Silver Bay Seafoods - Valdez, LLC | — | Mining & Resources | Series B | $22.2M | $500K | 2021 |
| MindImmune Therapeutics, Inc. | — | Pharmaceuticals | Series B | $21.3M | $61.2M | 2025 |
Robert Nelson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Nelson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.